Linkers & Payloads
- The shifting balance of innovation to identify the next leap is more likely from linker chemistry or payload diversity?
- Mapping where linker and payload decisions are genuinely coupled versus independent
- Beyond the cytotoxic paradigm: what immune-modulating and degrader payloads mean for the whole conjugate
- Designing the linker–payload unit for a target product profile rather than optimizing components in isolation
- Lessons from clinical linker/payload failures and the design rules they have taught the field
- The CMC and developability burden of increasingly complex linker–payload chemistries
- The competitive and IP landscape around proprietary linker and payload technologies